Next-generation treatment of acquired hemophilia A

Bibliography

• Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003;121:21-35
   PubMed Web of Science ®Google Scholar
• Coppola A, Favaloro EJ, Tufano A, et al. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 2012;38(5):433-46
   PubMedGoogle Scholar
• Franchini M, Mannucci PM. Acquired haemophilia A: a 2013 update. Thromb Haemost 2013;110(6):1114-20
   PubMedGoogle Scholar
• Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981;45:200-3
   PubMed Web of Science ®Google Scholar
• Collins P, Hirsch S, Baglin TP, et al. Acquired haemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007;109:1870-7
   PubMed Web of Science ®Google Scholar
• Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012;10(4):622-31
   PubMed Web of Science ®Google Scholar
• Baudo F, Collins P, Huth-Kuhne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) registry. Blood 2012;120(1):39-46
   PubMed Web of Science ®Google Scholar
• Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012;120(1):47-55
   PubMed Web of Science ®Google Scholar
• Collins P, Baudo F, Huth-Kuhne A, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010;3:161
   PubMedGoogle Scholar
• Collins PW, Chalmers E, Hart D, et al. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013;162(6):758-73
   PubMedGoogle Scholar
• Huth-Kuhne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009;94(4):566-75
   PubMed Web of Science ®Google Scholar
• Cohen AJ, Kessler CM. Acquired inhibitors. Bailleres Clin Haematol 1996;9:331-54
   PubMed Web of Science ®Google Scholar
• Franchini M, Gandini G, Di Paolantonio T, et al. Acquired hemophilia A: a concise review. Am J Hematol 2005;80:55-63
   PubMed Web of Science ®Google Scholar
• Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981;45:200-3
   PubMed Web of Science ®Google Scholar
• Bossi P, Cabane J, Ninet J, et al. Acquired haemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998;105:400-8
   PubMed Web of Science ®Google Scholar
• Yee TT, Pasi KJ, Lilley PA, et al. Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97. Br J Haematol 1999;104:909-14
   PubMed Web of Science ®Google Scholar
• Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol 2006;81:768-73
   PubMed Web of Science ®Google Scholar
• Tengborn L, Baudo F, Huth-Kühne A, et al. EACH2 registry contributors. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG 2012;119(12):1529-37
   PubMedGoogle Scholar
• Webert KE. Acquired hemophilia A. Semin Thromb Hemost 2012;38(7):735-41
   PubMedGoogle Scholar
• Sborov DW, Rodgers GM. Acquired hemophilia a: a current review of autoantibody disease. Clin Adv Hematol Oncol 2012;10(1):19-27
   PubMedGoogle Scholar
• Franchini M, Targher G, Montagnana M, et al. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 2008;395:14-18
   PubMed Web of Science ®Google Scholar
• Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia centre. Semin Thromb Hemost 2009;35:760-8
   PubMed Web of Science ®Google Scholar
• Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995;86:1811-19
   PubMed Web of Science ®Google Scholar
• Shetty S, Bhave M, Ghosh K. Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options. Autoimmun Rev 2011;10(6):311-16
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008;112:250-5
   PubMed Web of Science ®Google Scholar
• Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007;5:893-900
   PubMed Web of Science ®Google Scholar
• Collins PW. Therapeutic challenges in acquired factor VIII deficiency. ASH Education Book 2012;2012:369-74
   Google Scholar
• Mudad R, Kane WH. DDAVP in acquired haemophilia A: case report and review of the literature. Am J Haematol 1993;43:295-9
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G. The use of desmopressin in acquired haemophilia A: a systematic review. Blood Transfus 2011;9(4):377-82
   PubMed Web of Science ®Google Scholar
• Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993;81:1513-20
   PubMed Web of Science ®Google Scholar
• Giangrande PL. Porcine factor VIII. Haemophilia 2012;18:305-9
   PubMed Web of Science ®Google Scholar
• Franchini M, Coppola A, Tagliaferri A, et al. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013;39(7):772-8
   PubMedGoogle Scholar
• Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011;72:553-62
   PubMed Web of Science ®Google Scholar
• Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Blood 2014;124:3365-72
   PubMed Web of Science ®Google Scholar
• Franchini M, Sassi M, Dell’Anna P, et al. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors. Semin Thromb Hemost 2009;35(1):76-80
   PubMedGoogle Scholar
• Negrier C, Dechavanne M, Alfonsi F, et al. Successful treatment of acquired factor VIII antibody by extracorporeal immunoadsorption. Acta Haematol 1991;85:107-10
   PubMed Web of Science ®Google Scholar
• Jansen M, Schmaldienst S, Banyai S, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001;112:91-7
   PubMed Web of Science ®Google Scholar
• Tiede A, Klamroth R, Scharf RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2014. [Epub ahead of print]
   Google Scholar
• Franchini M, Mannucci PM. Inhibitor eradication with rituximab in haemophilia: where do we stand? Br J Haematol 2014;165:600-8
   PubMed Web of Science ®Google Scholar
• Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007;63:47-52
   PubMed Web of Science ®Google Scholar
• Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005;105(6):2287-93
   PubMedGoogle Scholar
• Lin VW, Novack A, Testa D, et al. The economic and clinical burden of acquired hemophilia A (AHA) [abstract]. Haemophilia 2014;20(Suppl 3):1
   Google Scholar
• Toschi V. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII. Curr Opin Mol Ther 2010;12:617-25
   PubMedGoogle Scholar
• Kempton CL, Abshire TC, Deveras RA, et al. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 2012;18(5):798-804
   PubMed Web of Science ®Google Scholar
• Kruse-Jarres R, ST-Louis J, Greist A, et al. Recombinant porcine sequence factor VIII (OBI-1): results from a prospective clinical study investigating the treatment of serious bleeds in patients with acquired hemophilia A [abstract]. Haemophilia 2014;20(Suppl 3):1
   PubMedGoogle Scholar
• Lozier JN, Nghiem K, Lee M, et al. Acquired haemophilia A after stem cell transplant for sickle cell disease: treatment with recombinant porcine factor VIII (OBI-1) and tolerance induction with rituximab/prednisone. Haemophilia 2014;20(2):e185-8
   PubMedGoogle Scholar
• Weimer T, Wormsbacher W, Kronthaler U, et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008;99:659-67
   PubMed Web of Science ®Google Scholar
• Golor G, Bensen-Kennedy D, Haffner S, et al. Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with Albumin (rVIIa-FP) in Healthy Volunteers. J Thromb Haemost 2013;11:1977-85
   PubMed Web of Science ®Google Scholar
• Mahlangu JN, Coetzee MJ, Laffan M, et al. Phase I, randomized, double-blind, placebo- controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost 2012;10:773-80
   PubMed Web of Science ®Google Scholar
• Møss J, Rosholm A, Laur_en A. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost 2011;9:1368-74
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Karim FA, Gorska-Kosicka M, et al. Anti-drug antibody formation in hemophilia patients with inhibitors after receiving recombinant activated FVII analogue (vatreptacog alfa). Haemophilia 2013;9(Suppl 2):10-82
   Google Scholar
• Parunov LA, Fadeeva OA, Balandina AN, et al. Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation. J Thromb Haemost 2011;9(9):1825-34
   PubMed Web of Science ®Google Scholar
• Gorczyca ME, Nair SC, Jilma B, et al. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost 2012;10(8):1581-90
   PubMed Web of Science ®Google Scholar
• Dockal M, Pachlinger R, Hartmann R, et al. Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antagonistic aptamer BAX 499 [abstract]. Blood (ASH Annual Meeting Abstracts) 2012;120:1104
   Web of Science ®Google Scholar
• Petersen LC. Hemostatic properties of a TFPI antibody. Thromb Res 2012;129:S44-5
   PubMed Web of Science ®Google Scholar
• Waters EK, Hilden I, Dhillon S, et al. The TFPI antibody, concizumab, improves thrombin generation in plasma from patients with hemophilia a, hemophilia B or inhibitors [abstract]. Haemophilia 2014;20(Suppl 3):82-3
   Google Scholar
• Hilden I, Lauritzen B, Sorensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012;119:5871-8
   PubMed Web of Science ®Google Scholar
• Muto A, Yoshihashi K, Takeda M, et al. The anti-factor IXa/X bispecific antibody ACE910 prevents spontaneous joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014;124(20):3165-71
   PubMed Web of Science ®Google Scholar
• Shima M, Hanabusa H, Taki M, et al. Safety and prophylactic efficacy profile of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, in Japanese hemophilia a patients both without and with inhibitors: first-in-patient phase 1 study. Blood (ASH Annual Meeting Abstracts) 2014;124-691
   Google Scholar